Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$3.45 - $8.77 $1.16 Million - $2.96 Million
-337,201 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.01 - $12.84 $964,155 - $1.55 Million
120,369 Added 55.51%
337,201 $2.74 Million
Q3 2021

Nov 15, 2021

BUY
$11.94 - $16.09 $131,817 - $177,633
11,040 Added 5.36%
216,832 $2.73 Million
Q2 2021

Aug 12, 2021

BUY
$14.36 - $20.93 $545,837 - $795,570
38,011 Added 22.66%
205,792 $3.18 Million
Q1 2021

May 17, 2021

BUY
$18.19 - $33.25 $2.21 Million - $4.04 Million
121,560 Added 263.0%
167,781 $3.39 Million
Q4 2020

Feb 12, 2021

BUY
$15.87 - $31.64 $24,915 - $49,674
1,570 Added 3.52%
46,221 $1.25 Million
Q3 2020

Nov 13, 2020

BUY
$15.7 - $20.84 $227,775 - $302,346
14,508 Added 48.13%
44,651 $826,000
Q2 2020

Aug 14, 2020

BUY
$8.21 - $21.02 $247,474 - $633,605
30,143 New
30,143 $537,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $89.2M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.